Analysis of serum microrna in patient with psoriasis

Introduction: Psoriasis is a chronic inflammatory disease of skin characterized by epidermal hyperproliferation, abnormal keratinocyte differantiation, angiogenesis and T cell proliferation in epidermis and dermis. It is not only a disease affecting skin but it can affect nails and joint as well. The pathogenesis of psoriasis involves genetic, environmental and immunological factors, but it is not fully understood . MiRNAs are an abundant class of highly conserved small nc-RNA molecules that modulate gene expression post-transcriptionally. MiRNAs act primarily within the cell, however; recent evidence has shown the presence of miRNAs in cell-free environment, including serum and plasma. Alterations in the expression of over 1000 genes have been described in psoriatic lesions. Moreover, recent studies have described a key role for small RNAs known as miRNAs in controlling the gene expression of inflammatory proteins in skin affected by psoriasis. MiRNAs have also been implicated in keratinocyte differentiation and T-cell function in psoriasis. Several attempts have been made to identify soluble biomarkers for psoriasis, however; there are still no specific biomarkers that can accurately predict disease progression and therapeutic response. Differentially expressed miRNAs likely influence many processes that are involved in psoriasis pathogenesis, such as epidermal differentiation (miR-125b, miR-21, miR- 203), angiogenesis (miR-21, miR-31, miR-378). Early studies on psoriasis specific miRNA expression were primarily confined to skin tissue samples. A few studies have investigated the miRNA expression in sera from patient with psoriasis. Aim: We aimed to analyze serum miRNA expression in patient with psoriasis and healthy controls, to determine the relationship between miRNA and disease and also, to explore miRNAs potential as blood biomarkers for psoriasis. Method: Study was planned to be a controlled one; other inflammatory skin conditions and systemic diseases were excluded. Study carried out in patients with chronic plaque psoriasis which were followed by Celal Bayar University, Dermatology Department during 1 years beginning from 2016. 35 patients included in this study. Routine blood tests were done to check for signs of inflammation and psoriasis comorbidities in addition to one EDTA tube which was sent the genetic laboratory to analyze of mikroRNA expression. Written informed consent was obtained from all subjects. The clinical and laboratory findings of patients with chronic plaque psoriasis was recorded one by one for each patient. The dependent variable of the study was chronic plaque psoriasis and independent variables was increasing and decreasing genes. Blood samples was collected into sterile, anticoagulant (EDTA) coated tubes and miRNA gene expression was studied by flow genetic laboratory. miR-19a, miR-19b, miR29a, miR-29b, miR-4729, miR-23a, miR-23b, miR-23c, miR-211, miR-204, miR-2277, miR-520, mir-524 and miR 4795 expression was analyzed by using RT-qPCR. Result: In this study, miR- 19a, miR-19b, miR-23a and miR-29a expression was found significantly down-regulated in psoriatic patient comparing to healthy control. The expressions of other miRNAs were not altered. There was no correlation between miRNA ekspression level and PASI score. Conclusion: Our result suggest that miR-19a, miR-19b, miR-23a and miR-29a may have an important role in pathogenesis of psoriasis vulgaris and also our data indicate that regulation of these miRNAs may be a potential therapeutic option in psoriasis.